NSABP B-43

Terminated

Return to Protocol Table

A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

Principal Investigator

Melody Cobleigh

Status

Terminated

Date Opened To Accrual

November 10, 2008

Date Closed To Accrual

December 8, 2014

Date of Study Termination

June 2, 2025


Disease Site

Breast [BR] Breast

Phase

III

Developmental Therapeutics

No

Primary Objective

To determine the value of trastuzumab given during radiation therapy (RT) compared to RT alone in preventing the subsequent occurrence of ipsilateral breast cancer recurrence, ipsilateral skin cancer recurrence, or ipsilateral DCIS
(IIBCR-SCR-DCIS) in women with HER2-positive DCIS resected by lumpectomy.

Patient Population

Women with HER2-positive ductal carcinoma in situ (DCIS) resected by lumpectomy

Target Accrual

2000

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.